Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine

Gene Therapy

Volumn 3, Issue 1, 1996, Pages 59-66

  Qin, H X ^a   Chatterjee, S K ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

cytokine; GM CSF; murine; tumor; vaccinia

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CANCER THERAPY; GENE THERAPY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALS; BASE SEQUENCE; CELL LINE; CLONING, MOLECULAR; DNA PRIMERS; FEMALE; GENE EXPRESSION; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNIZATION; LAC OPERON; MELANOMA; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; PLASMIDS; RECOMBINATION, GENETIC; TUMOR CELLS, CULTURED; VACCINES; VACCINIA VIRUS;

EID: 0030007925     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Russel SJ. Lymphokine gene therapy for cancer. Immunol Today 1990; 11: 196-200.
2. Zabner J et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993; 75: 207-216.
3. Chatterjee S, Johnson PR, Wong KK. Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated antisense vector. Science 1992; 258: 1485-1488.
4. Estin CD et al. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci USA 1988; 85: 1052-1056.
5. Kantor J et al. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 1992; 52: 6917-6925.
6. Bernards R et al. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci USA 1987; 84: 6854-6858.
7. Hareuveni M et al. Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc Natl Acad Sci USA 1990; 87: 9498-9502.
8. Moss B. Vaccinia virus: a tool for research and development. Science 1991; 252: 1662-1667.
9. Goebel JJ et al. The complete DNA sequence of vaccinia virus. Virology 1990; 179: 247-266.
10. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992, 10: 180-199.
11. Gansbacher B et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217-1224.
12. Fearon ER et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
13. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503-512.
14. Elkins K, Ennist DL, Winegar RK, Weir JP. In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice. Hum Gen Ther 1994; 5: 809-820.
15. Gansbacher B et al. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990; 50: 7820-7825
16. Colombo MP et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991; 173: 889-897.
17. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
18. Flexner C, Hugin A, Moss B. Attenuation of live recombinant vaccinia virus vectors by expression of human interleukin-2. In: Ginsberg H, Brown F, Lerner RA, Chanock RM (eds). Vaccine 88. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1988, pp 179-184.
19. Cochran M, Puckett C, Moss B. In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals. J Virol 1985; 54: 30-37.
20. Mackett M, Smith GL, Moss B. The construction and characterization of vaccinia virus recombinants expressing foreign genes. In: Glover DM (ed). DNA Cloning, vol. II. IRL Press: Oxford, 1985, pp 191-212.
21. Gough NM et al. Structure and expression of the mRNA for murine granulocyte-macrophage colony-stimulating factor. EMBO J 1985; 4: 645-653.
22. Shaw G, Kamen R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986; 46: 659-667.
23. Kozak M. Possible role of flanking nucleotide in recognition of the AUG initiator codon by eukaryotic ribosomes. Nucleic Acids Res 1981; 9: 5233-5252.
24. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B cell lymphoma. Nature 1993; 362: 755-758.
25. Kozak M. An analysis of vertebrate mRNA sequence: intimations of translational control. J Cell Biol 1991; 115: 887-903.
26. Moss B. Regulation of vaccinia virus transcription. Ann Rev Biochem 1990; 59: 661-688.
27. Altschul SF et al. Basic local alignment search tool. J Mol Biol 1990; 215: 403-410.
28. Hruby DE, Maki RA, Miller DB, Ball LA. Fine structure analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene. Proc Natl Acad Sci USA 1983; 80: 3411-3415.
29. Sambrook J, Fritsch FJ, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, 1989.
30. Mackett M, Smith GL, Moss B. Vaccinia, a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 1982; 79: 7415-7419.
31. Miller J. Experiments in Molecular Genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1972.
32. Corcoran D, Metcalf SJE, Handman E. GM-CSF produced by recombinant vaccinia virus or in GM-CSF transgenic mice has no effect in vivo on murine cutaneous leishmaniasis. J Parasitol 1988; 74: 763-767.
33. Jaffee EM et al. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 1993; 53: 2221-2226.
34. Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 1975; 35: 218-224.